0000950159-24-000103.txt : 20240307 0000950159-24-000103.hdr.sgml : 20240307 20240307065512 ACCESSION NUMBER: 0000950159-24-000103 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240307 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 24728107 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm THE CIGNA GROUP FORM 8-K
false 0001739940 0001739940 2024-03-07 2024-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

 

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) March 7, 2024

 

The Cigna Group

 

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of

 

incorporation)

001-38769

(Commission File Number)

82-4991898

(IRS Employer

Identification No.)

 


900 Cottage Grove Road

Bloomfield, Connecticut 06002

 

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code:

 

(860) 226-6000

 

Not Applicable

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

Outlook and Investor Day Information

On March 7, 2024, The Cigna Group (the “Company”) issued a press release noting that the Company will host its Investor Day, both in person in New York, New York and virtually, beginning at approximately 8:30 a.m. eastern time. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. During Investor Day, as well as in meetings with investors and analysts over the next several weeks, The Cigna Group officials expect to reaffirm projected full year 2024 consolidated adjusted revenues of at least $235 billion, and adjusted income from operations of at least $28.25 per share. This 2024 outlook includes the impact of expected future share repurchases and anticipated 2024 dividends. The Cigna Group officials also expect to raise long-term average annual adjusted EPS growth target to 10%-14%.

The Cigna Group previously discussed its full year 2024 outlook in its press release and investor presentation dated February 2, 2024 and during the related investor conference call. The press release, presentation and the conference call transcript are available on the Investor Relations page of the Company’s website located at www.thecignagroup.com. Forward-looking statements in these documents and the related call speak only as of the date they were made.

The Investor Day presentations are expected to begin on March 7, 2024 at approximately 8:30 a.m. eastern time and conclude by 12:30 p.m. eastern time.  Investors and analysts are invited to listen to the presentation free over the Internet via webcast by visiting the Investor Relations page of the Company’s website located at www.thecignagroup.com. The Investor Relations section of the Company’s website will also contain materials used during and relating to the Investor Day presentations, including definitions of certain metrics not determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and reconciliations of certain historic non-GAAP metrics to the most directly comparable GAAP measures.

Definitions and Financial Information

Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the underlying results of operations of the Company’s businesses and permits analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income from operations is defined as shareholders’ net income (or income before taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income.

Adjusted revenues is used by The Cigna Group’s management because it permits analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. Additional definitions and relevant reconciliations of The Cigna Group’s non-GAAP measures to their most directly comparable GAAP measure are set forth in the appendix to these materials.

Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income (including on a per share basis) or adjusted revenues to total revenues on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.

The Cigna Group currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board’s determination that the declaration of dividends remains in the best interests of the Company and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company’s financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be affected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.

This information, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as shall be expressly set forth by specific reference in such a filing.

 

 

   

 

 

 

 

 

 

 

 

 Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

  

The following exhibits are being furnished as part of this report:

 

Exhibit No. Description

 

 

  99.1 Press release dated March 7, 2024.

 

  104 Cover Page Interactive Data File (embedded within the Inline XBRL).
     

 

Forward-Looking Statements

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Current Report on Form 8-K (the “Report”), and oral statements made with respect to information contained in this Report, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations outlook for 2024 on a consolidated and per share basis; projected adjusted revenue outlook for 2024; projected adjusted earnings per share outlook on a long-term basis; projected capital deployment, including share repurchases and future dividends, including projected shareholder dividends for 2024; business strategy and strategic or operational initiatives (including our announced solutions or initiatives for certain health care challenges); and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of potential cyberattack or other privacy or data security incidents; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

 

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  THE CIGNA GROUP
   
Date:  March 7, 2024 By: /s/ Brian C. Evanko       
    Brian C. Evanko
    Executive Vice President, Chief Financial Officer, The Cigna Group, and President and Chief Executive Officer, Cigna Healthcare

  

 EX-99.1 2 ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

PRESS RELEASE

 

The Cigna Group Raises Long-Term Growth Target, and Launches New Innovative Solutions at 2024 Investor Day

 

Highlights:

·Raises long-term average annual adjusted EPS1 growth target to 10%-14%

 

·Affirms 2024 adjusted EPS1 guidance of at least $28.25

 

·Announces solutions and innovations for some of the greatest health care challenges: GLP-1 spend, mental health care access and support, and access to biosimilars

 

BLOOMFIELD, Conn., March 7, 2024 — Today, global health company The Cigna Group (NYSE:CI), will outline its growth and innovation strategies at its 2024 Investor Day. In addition, the company is raising its long-term average annual adjusted EPS1 growth target to 10%-14% and is reaffirming its 2024 adjusted EPS1 guidance of at least $28.25.

 

“With a strong track record of impact and performance, we have purposefully built The Cigna Group to sustain our leadership in improving choice, access and affordability, and clinical outcomes,” said David M. Cordani, chairman and CEO of The Cigna Group. “Our success – and confidence in our future – stems from our proven ability to evolve our company to meet the changing market needs and create value for those we serve.”

 

The company is also announcing a series of innovative solutions that address some of health care’s greatest challenges:

·Express Scripts by Evernorth, a leading pharmacy services provider, announced the industry’s first financial guarantee for GLP-1s, leveraging its deep supply chain expertise to help companies and other clients manage the rising costs of treating cardiodiabesity.
·Evernorth Behavioral Health announced a new mental health practice that provides value-based, outcome-driven care through a simpler care delivery experience.
·Evernorth Health Services plans to have a Humira biosimilar available for $0 out of pocket to eligible patients of Accredo, its leading specialty pharmacy, by the end of the year.

 

 

1 
 

EncircleRx Offers Industry-First Financial Guarantee To Manage Cost of GLP-1s

 

Evernorth is helping companies and client organizations manage the costly landscape of treating cardiodiabesity – the confluence of obesity, diabetes and cardiovascular disease - by launching the industry’s first financial guarantee for GLP-1s through EncircleRxSM. By providing financial predictability through a cost cap or savings guarantee, EncircleRx allows companies and organizations to better manage GLP-1 spend, which will help ensure access for eligible patients.

 

“Our industry-first financial guarantee offers employers and health plans greater predictability and control of their GLP-1 spend,” said Adam Kautzner, president of Express Scripts and Evernorth Care Management. “EncircleRx also gives employers and health plans access to our deep insights and clinical expertise to help ensure GLP-1s are accessed by patients who need them most – whether it’s to control their diabetes or achieve significant weight loss. Our clinically proven lifestyle modification program, coupled with GLP-1s, surrounds patients with support to help them achieve the best possible health outcomes.”

 

Expands Behavioral Value-Based Care With Launch of Evernorth Behavioral Care Group

 

Evernorth is launching a behavioral health practice to expand timely access to quality, in-network therapy. Evernorth Behavioral Care Group provides value-based, outcome-driven care through a simpler care delivery experience. The group is already treating patients in select states, with plans to scale fully by 2025.

 

Patients are guaranteed an appointment – either in person or virtually – within 72 hours of scheduling. This practice enables behavioral health clinicians to work with payers with greater ease, efficiency, and integration, reducing their administrative burden and empowering them to focus on patient care.

“The vast majority of people struggle to get help when they need it, and individual practitioners lack the tools and technology to make access easy and to measure quality,” said Eva Borden, president, Behavioral Health, Evernorth Health Services. “Evernorth is committed to building a care experience that quickly and seamlessly connects a patient with the right clinician, while empowering clinicians to focus on patient care by removing administrative burdens.”

2 
 

Plans To Have Humira Biosimilar Available at $0 Patient Out-of-Pocket Cost for Eligible Accredo Patients

 

In an important step toward driving significant long-term affordability and access, Evernorth Health Services plans to have a Humira biosimilar available for $0 out of pocket to eligible patients of its leading specialty pharmacy Accredo later this year.

“Biosimilars can help drive significant savings for health plans and patients,” said Matt Perlberg, president of the Evernorth Health Services pharmacy and care delivery businesses. “Because of the leading capabilities we have within Evernorth, our specialty pharmacy Accredo, and across the supply chain, we are uniquely positioned to make patients’ experiences as simple as possible. Accredo helps patients manage all elements of their specialty medication – from working with their health care provider, counseling on therapy, and administering their medications, to coordinating copay assistance and working with the patient’s health plan to secure coverage.”

 

Investor Day Webcast

 

The Investor Day will begin today at 8:30 a.m. ET and a live webcast of the presentation will be available at https://investors.thecignagroup.com/events-and-presentations/default.aspx in the Investor Relations section of The Cigna Group's website.

 

To listen to this presentation live on the Internet, visit https://investors.thecignagroup.com/events-and-presentations/default.aspx at least 15 minutes prior to the presentation to download and install any necessary audio software.

 

About The Cigna Group

 

The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has approximately 183 million customer relationships around the world. Learn more at thecignagroup.com.

 

 

3 
 

NOTES

 

1. Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the underlying results of operations of the Company’s businesses and permits analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income from operations is defined as shareholders’ net income (or income before taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income.

 

Management is not able to provide a reconciliation of adjusted income (loss) from operations to shareholders’ net income (including on a per share basis) because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders’ net income COULD vary materially.

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations outlook for 2024 on a consolidated and per share basis; projected adjusted earnings per share outlook on a long-term basis business strategy and strategic or operational initiatives (including our announced solutions or initiatives for certain health care challenges); and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect,"

 

4 
 

"project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

 

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of potential cyberattack or other privacy or data security incidents; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our

 

5 
 

significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

 

INVESTOR RELATIONS CONTACT:

Ralph Giacobbe

860-787-7968

Ralph.Giacobbe@TheCignaGroup.com

 

MEDIA CONTACT:

Justine Sessions

860-810-6523

Justine.Sessions@Evernorth.com

 

 

6 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 4 image_002.jpg GRAPHIC begin 644 image_002.jpg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end EX-101.SCH 5 ci-20240307.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 ci-20240307_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 ci-20240307_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 07, 2024
Entity File Number 001-38769
Entity Registrant Name The Cigna Group
Entity Central Index Key 0001739940
Entity Tax Identification Number 82-4991898
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 900 Cottage Grove Road
Entity Address, City or Town Bloomfield
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06002
City Area Code 860
Local Phone Number 226-6000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.01
Trading Symbol CI
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://thecignagroup.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ci-20240307.xsd ci-20240307_lab.xml ci-20240307_pre.xml cigna8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cigna8k.htm": { "nsprefix": "CI", "nsuri": "http://thecignagroup.com/20240307", "dts": { "schema": { "local": [ "ci-20240307.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ci-20240307_lab.xml" ] }, "presentationLink": { "local": [ "ci-20240307_pre.xml" ] }, "inline": { "local": [ "cigna8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://thecignagroup.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cigna8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cigna8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0000950159-24-000103-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950159-24-000103-xbrl.zip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end XML 18 cigna8k_htm.xml IDEA: XBRL DOCUMENT 0001739940 2024-03-07 2024-03-07 iso4217:USD shares iso4217:USD shares false 0001739940 8-K 2024-03-07 The Cigna Group DE 001-38769 82-4991898 900 Cottage Grove Road Bloomfield CT 06002 860 226-6000 false false false false Common Stock, Par Value $0.01 CI NYSE false